Introduction {#S1}
============

Alcohol abuse is a leading cause of preventable death and illness, and the economic cost of alcohol abuse is estimated to be \$185 billion annually in the USA alone^[@R1]^. Adoption and twin studies suggest that alcohol use disorders (AUDs) are 50-60% genetically determined^[@R2],[@R3]^. A growing body of research indicates that genetic differences in cerebellar processing and cerebellar responses to alcohol contribute to susceptibility to AUDs^[@R2],[@R4]-[@R6]^, but the mechanisms by which the cerebellum influences the development of AUDs are not known.

Insight into cerebellar contributions to AUD risk comes from studies of the low level of response (LLR) to EtOH phenotype, which is defined as requiring a higher dose of alcohol (EtOH) to achieve a given effect. EtOH-induced static ataxia (body sway), a form of cerebellar-dependent motor impairment, consistently shows LLR in individuals with a family history of AUDs compared to individuals without a family history of AUDs^[@R5],[@R6]^. Thus, low cerebellar sensitivity to EtOH may be a risk factor for AUDs. In support of this contention, the magnitude of EtOH-induced ataxia shows an inverse relationship with EtOH consumption and preference in some inbred strains of mice^[@R7],[@R8]^ as well as lines of rodents selected for differences in EtOH consumption^[@R9],[@R10]^ or in EtOH-induced motor impairment^[@R11]^. Importantly, cerebellar specific injections of various drugs can inhibit systemically administered EtOH induced-ataxia^[@R12]^, clearly indicating the central role of the cerebellum in mediating EtOH-induced ataxia.

Cerebellar granule cells (GCs) are the main integrators/processors of afferent input to the cerebellar cortex, making them powerful targets for pharmacological modulation of cerebellar processing^[@R13],[@R14]^. GCs exhibit traditional phasic GABA~A~R-mediated inhibitory postsynaptic currents (IPSCs), as well as the more recently discovered tonic form of GABA~A~R inhibition, mediated by extrasynaptic, α~6~δ subunit containing GABA~A~Rs^[@R14]-[@R18]^. The tonic form of GABA~A~R inhibition mediates 75% of total GC GABA~A~R inhibition, thereby powerfully controlling signal transmission through the cerebellar cortex^[@R14]^. Both the frequency of spontaneous GABAergic IPSCs (sIPSCs) and the magnitude of the tonic GABA~A~R-mediated current are enhanced by behaviorally relevant concentrations of EtOH^[@R19],[@R20]^. Therefore, genetic variation in the sensitivity of GC GABA~A~R inhibition to EtOH is a candidate mechanism for mediating the relationship between cerebellar LLR and AUD in humans, or high EtOH consumption in animal models. Unfortunately, almost all research on EtOH-induced potentiation of GC GABA~A~R inhibition has been done on Sprague-Dawley rats (SDRs), and little attention has been given to how the sensitivity of GC GABA~A~R inhibition to EtOH varies across species or divergent genotypes^[@R21]^. This neglect is a significant problem because SDRs have a high sensitivity, low EtOH consumption phenotype^[@R22]^, and thus may not be as relevant to AUD in humans.

We report here that EtOH can either increase or decrease GABA~A~R mediated inhibition of GCs, and the net impact across populations of GCs shifts, in a graded fashion, from strong enhancement in high sensitivity, low EtOH consuming rodents to suppression in low sensitivity, high EtOH consuming rodents. Furthermore, we found that the net impact of EtOH on GC GABA~A~R inhibition is determined by a balance between enhanced vesicular release of GABA (via EtOH inhibition of nitric oxide synthase (NOS)) and a direct suppression of GABA~A~Rs. The balance of these two processes is determined by differential expression of neuronal NOS (nNOS) and levels of postsynaptic PKC activity, both of which vary across rodent genotypes. These findings substantially alter the current dogma that the primary action of EtOH on GABA~A~R transmission is potentiation. Instead, our data indicate that EtOH can potentiate or suppress GABA~A~R transmission, and the polarity varies across rodent genotypes with divergent EtOH-related behavioral phenotypes.

Results {#S2}
=======

Mouse GC tonic current mediated by extrasynaptic GABA~A~Rs {#S3}
----------------------------------------------------------

To determine if EtOH consumption phenotype is associated with differences in GC GABA~A~R sensitivity to EtOH, we made voltage-clamp recordings (Vh = -60mV, with ECl= ∼ 0mV, see methods) from GCs in cerebellar slices obtained from alcohol naïve, prototypical high and low EtOH consuming mice, C57BL/6J (B6) and DBA/2J (D2) mice respectively^[@R7]^. First, we characterized the basal properties of GABA~A~R-mediated inhibition in GCs from these two strains of mice. Similar to the well characterized SDR GCs, B6 and D2 GCs exhibit phasic sIPSCs and a powerful tonic current (tonic current amplitude= B6: 26.74 ± 4.27 pA; D2: 22.90 ± 2.64 pA, *n* = 12 cells from 5 animals each; see [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} for current measuring methodology), both mediated by GABA~A~Rs as evidenced by their blockade by the GABA~A~R antagonist, GABAzine (10μM, [Fig. 1a,g](#F1){ref-type="fig"}). The GC tonic GABA~A~R current is thought to be mediated by extrasynaptic GABA~A~Rs containing the α6 and δ subunit^[@R14]-[@R16],[@R18]^, but this has not been fully established in B6 GCs and has not been examined at all in D2 GCs. We used confocal microscopy to examine B6 and D2 cerebellar slices immunostained with antibodies to the GABA~A~R α6 and δ subunit, and found that both subunits are richly and exclusively expressed by GCs in both strains of mice, particularly on their dendritic terminals ([Fig. 1b](#F1){ref-type="fig"} α6; [1d](#F1){ref-type="fig"} δ). Furthermore, in both strains of mice, the tonic current was reduced by furosemide (100μM, at which concentration it is specific for GABA~A~Rs containing the α6 subunit^[@R14],[@R23]^; [Fig. 1c,g](#F1){ref-type="fig"}, furosemide block of current= B6: 17.24 ± 2.16 pA; D2: 13.99 ± 1.75 pA, *n* = 17 cells each), and was enhanced by the GABA~A~R agonist THIP (500nM, which at concentrations up to 1μM is specific for GABA~A~Rs containing δ subunits^[@R16]^; [Fig. 1e,g](#F1){ref-type="fig"}, THIP induced current= B6: 45.41 ± 3.93 pA, *n* = 18; D2: 33.67 ± 7.40 pA, *n* = 10 cells). Finally, diazepam (300nM), which potentiates the response of α1 containing receptors, but not α6 containing receptors, and does not affect the tonic GABA~A~R current in SDR GCs^[@R14],[@R24]^, did not affect the tonic GABA~A~R current in D2 or B6 mouse GCs ([Fig. 1f,g](#F1){ref-type="fig"};, D2: -0.08 ± 0.34 pA, *n* = 9 cells from 3 animals, *P* = .82; B6: -0.39 ± 0.57 pA, *n* = 7 cells from 2 animals, *P* = 0.52, one-sample *t*-tests). In the same cells, diazepam increased the magnitude and decay time of sIPSCs ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}), confirming its efficacy at diazepam-sensitive synaptically located α1 containing GABA~A~Rs. These data indicate that, similar to previous reports in SDR GCs, both B6 and D2 GCs exhibit tonic GABA~A~R currents mediated by extrasynaptic α6δ-containing receptors. There were no detectable differences between B6 and D2 GC GABA~A~R mediated tonic currents or sIPSCs ([Fig. 1g](#F1){ref-type="fig"} **and** [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}, all *P* \> 0.05).

Opposite actions of EtOH on GC tonic GABA~A~R currents {#S4}
------------------------------------------------------

Bath application of EtOH to SDR cerebellum increases the frequency of GC sIPSCs and the magnitude of the tonic GABA~A~R current ([Fig. 2a](#F2){ref-type="fig"})^[@R19],[@R20]^. Similar to SDR GCs, in some B6 and D2 GCs, bath application of 52mM EtOH caused an increase in the frequency of sIPSCs and an associated potentiation of the tonic GABA~A~R current ([Fig. 2b,e](#F2){ref-type="fig"}). However, in 41-45% of both B6 (16/39 cells) and D2 (14/31 cells) GCs, EtOH had no discernible effect on the tonic current ([Fig. 2c,e](#F2){ref-type="fig"}) or the frequency of sIPSCs (discussed in greater detail below). Surprisingly, in 44% of B6 (17/39 cells) GCs and in 10% of D2 GCs (3/31 cells), EtOH actually suppressed the tonic GABA~A~R current ([Fig. 2d,e](#F2){ref-type="fig"}). Importantly, EtOH did not affect the holding current in any species of GC when GABA~A~Rs were blocked by GABAzine (10μM, D2: *n* = 8 cells from 3 animals, B6: n = 11 cells from 4 animals, and SDRs: n = 32 cells from 8 animals, [Fig. 2f,g](#F2){ref-type="fig"}), confirming that EtOH-induced inward and outward currents are due to potentiation and suppression of the tonic GABA~A~R current respectively. To determine the overall impact on a population of GCs, and hence the output of the cerebellum (the sole output of the cerebellar cortex is via the Purkinje cell, whose output is influenced by ∼10^5^ GCs^[@R14],[@R25]^) we calculated the mean response of all cells from each type of rodent ([Fig. 2h](#F2){ref-type="fig"}). The averaged impact of EtOH on the GABA~A~R tonic current for a population of neurons was significantly different between strains (*H*(2) = 49.54, *P* \< .001, by Kruskal-Wallis) with the average for SDR and D2 GCs being potentiation (increase in tonic current = SDR: 4.65 ± 0.51 pA, *n* = 47 cells; D2: 2.51 ± 0.84 pA, *n* = 31 cells), whereas, the average impact on B6 GC tonic current was suppression (reduced by 2.32 ± 1.30 pA, *n* = 39 cells). Thus, 52mM EtOH will suppress transmission through the cerebellar cortex in low EtOH consuming SDRs and D2 mice, but it will enhance transmission through the cerebellar cortex in high EtOH consuming B6 mice^[@R13],[@R14]^.

Although the correspondence between GC GABA~A~R response phenotype and EtOH consumption phenotype is quite striking, to determine if this potential relationship is generalizable, we examined GC GABA~A~R responses to EtOH in the first replicate line of WSP and WSR mice (WSP1 & WSR1), which were bred for divergence in sensitivity to EtOH withdrawal phenotype but have a similar EtOH consumption phenotype that is intermediate between the low EtOH consuming D2 mice and SDRs and the high EtOH consuming B6 mice ([Fig. 2i](#F2){ref-type="fig"})^[@R26]^. While the GC GABA~A~R response to EtOH varied significantly across strains (*H*(4) = 59.03, *P* \< .001, by Kruskal-Wallis), it was similar in WSP1 (reduced by 0.49 ± 1.12 pA, *n* = 9 cells from 2 animals) and WSR1 mice (reduced by 1.50 ± 1.34 pA, *n* = 7 cells from 2 animals, *P* = .57, unpaired *t*-test), and fell between SDR/D2 and B6 responses, being on average slightly suppressed ([Fig. 2i](#F2){ref-type="fig"}). Thus, the net impact of EtOH on GABA~A~R transmission in a population of GCs varies from strong potentiation in low EtOH consuming SDRs and D2s, to strong suppression in high EtOH consuming B6s, with intermediate impact in moderate EtOH consuming WSR1 and WSP1 mice.

In the preceding experiments, we used a relatively high concentration of EtOH (52mM) to maximize our chances of discovering potentially subtle differences in responses across genotypes. However, while blood alcohol concentrations (BECs) reach 52mM in many non-choice rodent experiments (delivery of 2g/kg EtOH leads to BECs of 45-55mM, depending on species^[@R27]^), voluntary consumption of EtOH in rodents and humans more typically leads to BECs in the range of 5-25mM. To determine if the two types of response are activated by BECs achieved during voluntary EtOH consumption, we constructed dose response curves in B6 mouse and SDR GCs, which respectively exhibit predominantly suppression and exclusively enhancement ([Fig. 2j,k](#F2){ref-type="fig"}). As reported by others^[@R19],[@R20]^, in SDR GCs, concentrations of EtOH as low as 9mM (as would be achieved in an adult human consuming two units of alcohol) significantly enhance the magnitude of tonic GABA~A~R currents, and the degree of enhancement dose dependently increases until plateauing at about 52mM ([Fig. 2j,k](#F2){ref-type="fig"}; 9mM: 0.81 ± .20 pA, *n* = 21 cells; 31mM: 1.85 ± .38 pA, *n* = 22 cells; 52mM: 4.65 ± .51 pA, *n* = 47 cells; 79mM: 6.14 ± 1.29 pA, *n* = 15 cells generated from a minimum 3 animals/condition). Conversely, EtOH significantly suppresses the magnitude of tonic GABA~A~R current in the majority of B6 GCs, starting at 9mM and plateauing at 52mM ([Fig. 2j,k](#F2){ref-type="fig"}; 9mM: -0.79 ± 0.19 pA, *n* = 23 cells; 31mM: -1.38 ± 0.31 pA, *n* = 24 cells; 52mM: -3.37 ± 1.46 pA, *n* = 39 cells; 79mM: -2.62 ± 0.96 pA, *n* = 8 cells generated from a minimum 3 animals/condition). The magnitude of the EtOH-induced current in both directions was tightly and significantly correlated with the magnitude and polarity of the EtOH-induced change in noise variance ([Fig. 2l](#F2){ref-type="fig"}; Pearson correlation, *r* = 0.79, *P* \< 0.001, *n* = 79 cells from 5 SDRs, 10 D2s, and 10 B6s). Combined with the fact that EtOH does not induce any detectable currents in either direction in the presence of the GABA~A~R antagonist GABAzine ([Fig. 2f,g](#F2){ref-type="fig"}), these data confirm that the EtOH-induced shifts in macroscopic current are mediated by enhancement and suppression of the opening of GABA~A~R receptor channels. Thus, both suppression and enhancement of GABA~A~R-mediated tonic currents can occur in response to recreationally/clinically relevant concentrations of EtOH.

EtOH inhibition of nNOS increases Golgi cell firing {#S5}
---------------------------------------------------

As has been shown previously in SDR GCs, blocking action potentials with TTX (500nM) abolishes EtOH-induced enhancement of GC sIPSC frequency and tonic GABA~A~R current ([Fig. 3a,b](#F3){ref-type="fig"})^[@R19]^. Thus, the increase in both sIPSCs and tonic GABA~A~R current are due to increased action-potential driven, vesicular GABA release from Golgi cells (the GABAergic input to GCs), but the mechanisms mediating increased Golgi cell firing are not fully understood^[@R19],[@R28]^. Biochemical and behavioral studies have determined that EtOH inhibits cerebellar nitric oxide synthase (NOS), and the inhibition of cerebellar NOS mediates EtOH-induced ataxia^[@R12],[@R29]^, but the underlying mechanisms are not known. A recent study found that blocking NOS increases GC sIPSC frequency and tonic GABA~A~R current magnitude (which we confirm in [Fig. 3c,d](#F3){ref-type="fig"})^[@R30]^, very similar to what we and others observe for the response to EtOH ([Fig. 2a](#F2){ref-type="fig"}). We therefore reasoned that the EtOH-induced increase in GABA~A~R transmission may be mediated by inhibition of NOS. In support of our hypothesis, blocking NOS with the substrate inhibitor L-nitroarginine (L-NA, 300μM) significantly inhibited the EtOH-induced increase in sIPSC frequency and tonic GABA~A~R current in both SDRs and D2s ([Fig. 3e,f](#F3){ref-type="fig"}, all *P* \< .05). To ensure that the block by L-NA is a true pharmacological blockade of EtOH actions at NOS, and not simply occlusion of the response to EtOH due to saturation of the vesicular GABA release machinery (since blocking NOS increases vesicle release, [Fig. 3c](#F3){ref-type="fig"}), we conducted control experiments with nicotine. Nicotine (500nM) activates Golgi cell nicotinic acetylcholine receptors, which excites Golgi cells^[@R17]^, thereby increasing vesicular GABA release and resultant increases in tonic GABA~A~R currents ([Fig. 3g](#F3){ref-type="fig"}). In contrast to the impact on EtOH, blocking NOS did not affect nicotine-induced increases in GC tonic GABA~A~R currents ([Fig. 3g](#F3){ref-type="fig"}). Thus, the block by L-NA of EtOH-induced enhancement of IPSCs and tonic GABA~A~R currents is specific, and not due to occlusion by saturation of the system.

Our data suggest that EtOH-induced increases in GC IPSC frequency and tonic GABA~A~R current magnitude are mediated by EtOH suppression of a tonic production of NO that under control conditions limits the rate of vesicular GABA release. To further substantiate this notion, we used a fluorescent biochemical assay of cellular NO production, and tested whether NO is tonically generated in the GC layer, and whether EtOH suppresses such NO production ([Fig. 4](#F4){ref-type="fig"}). DAF-FM diacetate is an NO-sensitive fluorophore that is cell permeant until deacetylated by intracellular esterases, resulting in its intracellular accumulation. DAF-FM is essentially non-fluorescent until it reacts with NO, whereupon its fluorescence quantum yield increases 180 fold, making it an ideal intracellular sensor of \[NO\]. Cerebellar slices were soaked for 30 minutes in ACSF supplemented with DAF-FM (1μM; *n* = 20 slices from 2 animals) alone, DAF-FM + the NOS antagonist, L-NA (300μM; *n* = 22 slices from 2 animals), or DAF-FM + EtOH (52mM; *n* = 20 slices from 2 animals). Slices were then fixed, and analyzed with confocal microscopy. 3-D projections of confocally acquired images of DAF-FM treated slices revealed robust fluorescence throughout the GC layer and in the white matter axon tracks innervating the GC layer ([Fig. 4a](#F4){ref-type="fig"}). Slices treated with DAF-FM + L-NA exhibited a similar pattern of fluorescence emission, but the intensity was significantly reduced compared to DAF-FM alone (*P* \< 0.001; [Fig. 4b,d](#F4){ref-type="fig"}), confirming that the fluorescence signal is generated by NO production by NOS. EtOH (52mM) also significantly reduced the intensity of fluorescence emission without noticeably affecting the pattern (*P* \< 0.001 by unpaired *t*-test; [Fig. 4c,d](#F4){ref-type="fig"}). Thus, there is a tonic production of NO in the GC layer, and EtOH substantially inhibits that production.

Our data indicate that EtOH-induced increase in vesicular GABA release is triggered by blocking NO production, but is dependent on Golgi cell action potential (AP) firing (since it is abolished by TTX, [Fig. 3a,b](#F3){ref-type="fig"}). This raises the question of whether EtOH block of NOS causes the increase in Golgi cell AP firing that drives increased GABA release. To test this possibility, we made current-clamp recordings of Golgi cell responses to EtOH and NOS antagonists ([Fig. 5](#F5){ref-type="fig"}). Under control conditions, with appropriate current injection (mean = 21.8 ± 18.6 pA), Golgi cells stably fired APs (mean frequency = 0.7 ± 0.2 Hz, n = 12 cells from 4 animals; [Fig. 5a,b](#F5){ref-type="fig"}, **top panels**). Bath application of an NOS antagonist (L-NMMA, 200μM) or EtOH (52mM) significantly increased Golgi cell AP firing frequency (L-NMMA-induced increase = 26.7 ± 6.1%, *n* = 4 cells from 2 animals; EtOH-induced increase = 53.6 ± 14.1%, *n* = 8 cells from 4 animals; [Fig. 5a,b,d](#F5){ref-type="fig"}). Pretreatment with another NOS antagonist (L-NA, 300μM) also increased Golgi cell firing frequency, and prevented further increases by EtOH (EtOH-induced change = -10.6 ± 8.3%, *n* = 9 cells from 3 animals; [Fig. 5c,d](#F5){ref-type="fig"}). Thus, EtOH inhibition of NO production increases Golgi cell AP firing, thereby driving EtOH-induced increases in GC IPSC frequency and tonic GABA~A~R current magnitude.

Collectively, our data indicate that the EtOH-induced increase in GC sIPSCs and tonic GABA~A~R current is driven by increased Golgi cell AP firing, consequent to EtOH suppression of basal NO production. We therefore hypothesized that lower NOS expression and consequent NO production could underlie the relative lack of potentiation of GABA~A~R inhibition in B6 GCs compared to SDR and D2 GCs ([Fig. 2e](#F2){ref-type="fig"}). Accordingly, we used neuronal NOS (nNOS) immunohistochemistry and confocal microscopy to examine the expression and distribution of nNOS in SDR, D2 mouse and B6 mouse cerebellum ([Fig. 6a-g](#F6){ref-type="fig"}). nNOS expression is widespread and confluent in the granule cell layer of the SDR and D2 cerebellum, primarily in a ring-like pattern, encircling GC nuclei stained with Hoechst ([Fig. 6a,c](#F6){ref-type="fig"}), and in the cytoplasm of Golgi cell somas (identified by their larger size and expression of the GABA synthetic enzyme GAD65/67; [Fig. 6e](#F6){ref-type="fig"}). Although similar ring-like staining was seen in B6 cerebellum, it was greatly restricted, and there were frequent dark patches, or lack of staining throughout the B6 GC layer ([Fig. 6b](#F6){ref-type="fig"}), and the staining intensity in individual Golgi cell somas also appeared less intense ([Fig. 6f](#F6){ref-type="fig"}). Importantly, nNOS signal was completely absent in slices from mice in which the nNOS gene was deleted, confirming the specificity of our antibody ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). Although interpreting differences in immunostaining intensity across preparations can be problematic, given the stark qualitative differences, we developed two methods to quantify nNOS expression levels around GCs and in Golgi cell somas respectively. Since nNOS expression around GC somas appeared to reflect an all or nothing absence or presence of nNOS at various points around the GC soma perimeter, rather than a confluent difference in expression level at all points, we quantified the degree of GC encirclement. To do this, we adjusted the gain of each image to equalize peak fluorescence intensities across slices, and then calculated the degree of GC encirclement for every GC in the image (see [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"} for details). The degree of GC encirclement by nNOS staining differed between groups (*H*(2) = 2290.13, *P* \< .001) and was significantly smaller in B6 slices compared to SDR and D2 slices ([Fig. 6d](#F6){ref-type="fig"}, **both** *P* \< 0.001 by Dunn\'s method of multiple comparisons). Conversely, since the pattern of nNOS staining in Golgi cell somas was qualitatively similar across species, but appeared less intense in B6 mouse Golgi cells, we quantified overall Golgi cell nNOS staining intensity. To reduce potential variability caused by differences in antibody penetration or light scattering across preparations we normalized nNOS staining intensity to the staining intensity of GAD 65/67 in the same cell. The ratio of the mean intensity (across the entire Golgi cell soma) of nNOS staining relative to GAD 65/67 staining is significantly smaller in B6 mouse Golgi cells compared to either D2 mouse or SDR Golgi cells ([Fig. 6g](#F6){ref-type="fig"}; **main effect of group, *F*(2,18) = 31.03,** *P* \< 0.001 by one-way ANOVA and *P* \< .001 for both pairwise comparisons for SDR and D2 compared to B6). Thus, the level of nNOS expression in Golgi cell bodies, as well as in GC somas that densely surround Golgi cell somas, dendrites, and axons ([Fig. 6e,f](#F6){ref-type="fig"}), is significantly reduced in B6 mice compared to D2 mice and SDRs. Given the diffusible nature of NO, both compartments could influence the Golgi cell target that suppresses Golgi cell AP firing, and thus the reduction in both compartments in B6 mice could explain the absence of EtOH-induced enhancement of GC sIPSCs and tonic GABA~A~R current ([Fig. 2e,h](#F2){ref-type="fig"}).

To test whether the observed differences in nNOS immunostaining manifest as reduced NOS function, we used GC GABA~A~R current responses to pharmacological inhibition of NOS as a bioassay of NOS function ([Fig. 6h-l](#F6){ref-type="fig"}). In keeping with reduced expression of nNOS in B6 cerebellum, blocking NOS directly, with the NOS substrate antagonist L-NMMA (200μM) produced a significantly smaller potentiation of sIPSC frequency and tonic GABA~A~R current in B6 GCs (increase in sIPSC frequency = 2.76 ± 7.55%; tonic current = 2.25 ± 0.47 pA, *n* = 11 cells from 4 animals) compared to SDR (increase in sIPSC frequency = 120.37 ± 53.94%; tonic current = 6.20 ± 1.39 pA, *n* = 16 cells from 7 animals) and D2 GCs (increase in sIPSC frequency = 102.47 ± 46.08%; tonic current = 4.97 ± 0.82 pA, *n* = 17 cells from 4 animals; *P* \< 0.05 by Mann-Whitney U tests; [Fig. 6k,l](#F6){ref-type="fig"}).

Although reduced expression of nNOS could alone account for the lack of physiological response to EtOH in B6 mice, another possible contribution is reduced activity of the nNOS that is expressed. To test this possibility, we treated slices with L-arginine, a rate limiting reactant in the production of NO by NOS. In SDR slices, L-arginine (100μM) enhanced EtOH-induced increases in sIPSC frequency and tonic GABA~A~R current magnitude ([Supplementary Fig. 5a,c,d](#SD1){ref-type="supplementary-material"}), suggesting that endogenous levels of L-arginine are rate limiting for NO production in the SDR cerebellum. In contrast, L-arginine did not affect the actions of EtOH on GABA~A~R currents in B6 mice ([Supplementary Fig. 5b,c,d](#SD1){ref-type="supplementary-material"}). Taken together, the data suggest that the absence of potentiation of GC GABA~A~R transmission in ∼85% of B6 GCs ([Fig. 2e](#F2){ref-type="fig"}) is primarily due to a lower level of expression of nNOS, the inhibition of which mediates EtOH-induced potentiation of GABA~A~R transmission in SDR and D2 GCs.

Postsynaptic EtOH actions suppress tonic GABA~A~R currents {#S6}
----------------------------------------------------------

While differences in nNOS expression explain the relative lack of potentiation of GC GABA~A~R transmission in B6 GCs, it does not explain the suppression of GC GABA~A~R transmission observed in ∼45% of B6 GCs and ∼10% of D2 GCs ([Fig. 2e](#F2){ref-type="fig"}). Since EtOH-induced potentiation of GC tonic GABA~A~R current is due to action-potential dependent increased vesicular release of GABA ([Fig. 3a,b](#F3){ref-type="fig"}), we considered that suppression of the tonic current might be mediated by suppression of vesicular release of GABA. However, the sIPSC frequency was not suppressed in B6 GCs that showed EtOH-induced suppression of the tonic GABA~A~R current ([Fig. 7a](#F7){ref-type="fig"}). Furthermore, blocking action potentials with TTX did not affect the EtOH-induced suppression of tonic GABA~A~R current in B6 GCs ([Fig. 7b,c](#F7){ref-type="fig"}). Interestingly, in D2 GCs, TTX not only blocked the EtOH-induced potentiation of tonic GABA~A~R current, but it converted potentiation into suppression, similar to EtOH actions in B6 GCs ([Fig. 7b,c](#F7){ref-type="fig"}; EtOH-induced current in TTX in SDR: 0.09 ± 0.15 pA, *n* = 11 cells from 6 animals; B6: 2.77 ± 1.26 pA, *n* = 13 cells from 3 animals; D2: 2.71 ± 1.00, *n* = 9 cells from 2 animals). These data indicate that EtOH can inhibit tonic GABA~A~R currents independent of vesicular GABA release, and inhibition is dominant in B6 GCs, absent in SDR GCs and present in D2 GCs but typically obscured by EtOH-induced increases in GABA release similar to what is observed in SDR GCs.

Suppression of tonic GABA~A~R currents without corresponding changes in vesicular GABA release is suggestive of a direct action of EtOH on the extrasynaptic GABA~A~Rs that generate tonic GABA~A~R inhibition. However, changes in extracellular GABA concentration can occur independent of changes in vesicular release^[@R17]^. To circumvent potential actions of EtOH on GABA release or uptake mechanisms, and directly test whether EtOH suppression of tonic GABA~A~R currents is via direct actions in the postsynaptic cell, we conducted nucleated patch experiments, whereby the GC is extracted from the slice with the recording electrode ([Fig. 7d-f](#F7){ref-type="fig"}). We then bath applied a low concentration of GABA (100nM, which should only activate high affinity α6/δ containing GABA~A~Rs^[@R16]^) to isolated GCs, and examined responses to EtOH. In addition to visual determination of physical isolation, we confirmed that GC somas were functionally isolated from the slice by the disappearance of tonic GABA~A~R currents and sIPSCs ([Fig. 7d](#F7){ref-type="fig"}). Using this approach, for B6 GCs in which EtOH suppressed the tonic GABA~A~R current under whole-cell recording conditions within the slice (% suppression of tonic GABA~A~R current = 15.50 ± 2.27%, *n* = 20 cells from 6 animals), EtOH also significantly suppressed subsequent responses of isolated GCs to exogenous GABA, and to a similar degree (% suppression of GABA-induced current = 20.29 ± 7.76%, *n* = 6 cells from 2 animals; [Fig. 7e,f](#F7){ref-type="fig"}). Upon washout of exogenous GABA, subsequent application of GABAzine did not generate any detectable currents ([Fig. 7e](#F7){ref-type="fig"}), confirming that physically isolated GCs were not affected by endogenous GABA release from the slice. These results unequivocally demonstrate that EtOH can act directly on the postsynaptic cell to suppress extrasynaptic GABA~A~R tonic current responses to a fixed concentration of GABA.

Low GC PKC activity enables postsynaptic EtOH action {#S7}
----------------------------------------------------

Because tonic GABA~A~R currents in B6 and D2 mouse, and SDR GCs appear to be mediated by similar receptor subunits (α6βxδ; [Fig. 1](#F1){ref-type="fig"}), but show a differential sensitivity to direct suppression by EtOH, we considered postsynaptic modulatory mechanisms that might alter GABA~A~R sensitivity to EtOH. Previous studies showed that genetic deletion of PKCγ reduced EtOH stimulation of GABA~A~R-mediated Cl^-^ fluxes in a cerebellar microsac assay^[@R31]^, but the microsac Cl^-^ flux assay does not provide any information about the cell types involved, the underlying type of GABA~A~R currents or the responsible GABA~A~Rs. In particular, with a mixed population of cells and GABA~A~Rs, it is possible that the reported global reduction of EtOH stimulation is achieved by increasing EtOH suppression of a subset of GABA~A~Rs, i.e. those mediating tonic GABA~A~R currents in GCs (PKCγ is heavily expressed in all cell layers of the cerebellum^[@R32]^). To test this possibility, we determined whether blocking PKC in SDR GCs converted their normally insensitive tonic GABA~A~R currents to being sensitive to EtOH-induced suppression ([Fig. 8a,c](#F8){ref-type="fig"}). In the presence of TTX (to isolate direct suppressive actions of EtOH), addition of the PKC inhibitor, Calphostin C (100nM), to the recording electrode solution, transformed SDR GCs such that EtOH reduced the magnitude of the tonic GABA~A~R current (-1.03 ± 0.41 pA, *n* = 20 cells from 5 animals, *P =* .022) to a similar degree to what is observed in untreated B6 GCs (*P* = .47; [Fig. 8a,c](#F8){ref-type="fig"}). Thus, insensitivity of SDR GC GABA~A~R tonic currents to direct suppression by EtOH is a consequence of ongoing postsynaptic PKC activity. We therefore tested whether activating postsynaptic PKC in B6 GCs prevents EtOH suppression of tonic GABA~A~R currents ([Fig. 8b,c](#F8){ref-type="fig"}). As predicted, in recordings from B6 GCs (in TTX), including the phorbol esther PKC activator, PMA (100nM), in the recording electrode, abolished EtOH suppression of tonic GABA~A~R currents (0.02 ± 0.22, *n* = 8 cells from 2 animals, *P* = 0.94 by unpaired *t*-tests; [Fig. 8b,c](#F8){ref-type="fig"}). The actions of PKC on GABA~A~R currents is specific to their sensitivity to EtOH, because neither inclusion of PMA in B6 GCs nor Calphostin C in SDR GCs affected the baseline magnitude of tonic GABA~A~R current (SDR control = 7.80 ± 1.42 pA; SDR Calphostin C = 7.75 ± 1.16 pA; B6 control = 10.97 ± 0.66 pA; B6 PMA = 8.30 ± 2.60 pA; all *P* \> 0.05). Our data indicates that EtOH can directly suppress tonic GABA~A~R currents in all genotypes tested, but such direct suppression is prevented by elevated postsynaptic PKC activity, whether it occurs naturally, as in SDRs, or it is pharmacologically induced in rodent genotypes with lower basal PKC activity.

To determine the relative importance of PKC regulation of EtOH direct suppression versus nNOS regulation of EtOH enhancement (via increased GABA release), we repeated the PKC experiments in B6 mouse and SDR GCs under control conditions (i.e. without TTX; [Fig. 8d](#F8){ref-type="fig"}). In recordings of SDR GCs with Calphostin C in the recording electrode, although EtOH still enhanced the tonic GABA~A~R current, the enhancement was significantly less than for control cells (Calphostin C = 1.81 ± 0.60 pA, *n* = 16 cells from 3 animals, *P* = .003; [Fig. 8d](#F8){ref-type="fig"}). Conversely, in recordings of B6 GCs with PMA in the recording electrode, EtOH no longer suppressed the tonic GABA~A~R current, but rather slightly increased it (PMA = 0.67 ± 0.46 pA, *n* = 6 cells from 2 animals, *P* = .089 by Mann-Whitney U tests; [Fig. 8d](#F8){ref-type="fig"}). Combined with the nNOS experiments above, the data confirm that the net response to EtOH is determined by the balance between EtOH-induced increases in GABA release (via inhibition of nNOS) and direct suppression of postsynaptic GABA~A~Rs, with genetic variations in the two processes determining net response phenotype.

Discussion {#S8}
==========

Genetic variation in response to EtOH {#S9}
-------------------------------------

Genetic contribution to AUDs must, at some level, manifest as a differential response to EtOH, but little is known about the underlying neural substrates. Here we used patch-clamp recording in brain slices to directly assess differences in EtOH-related neural mechanisms across rodent genotypes with documented divergent EtOH related behaviors. We focused on the cerebellum because the severity of EtOH-induced disruption of cerebellar dependent behaviors is inversely related to risk for developing AUDs in humans^[@R5],[@R6]^ and excessive EtOH consumption in many rodent models^[@R7]-[@R11]^. We found that the impact of EtOH on GC GABA~A~R transmission ranges from strong potentiation in high EtOH sensitivity/low EtOH consuming SDRs and D2s to strong suppression in low sensitivity/high consuming B6s, with intermediate impact in moderate sensitivity/moderate consuming WSR1 and WSP1 mice ([Fig. 2i](#F2){ref-type="fig"}). While there are many factors that influence EtOH consumption by rodents, including taste^[@R33],[@R34]^, to our knowledge this is the first example of a cellular response to EtOH that varies in magnitude and polarity in parallel with EtOH behavioral phenotypes. And while it is unlikely that any one molecular process or brain region will fully explain a given EtOH phenotype, that a relationship between cellular response to EtOH and EtOH consumption ([Fig. 2i](#F2){ref-type="fig"}) holds across species (rats and mice), across inbred mice strains (B6 and D2), and across selected lines of mice (WSR and WSP) suggests that there is some overlap in the genes that influence EtOH consumption and GC GABA~A~R responses to EtOH. Importantly, in contrast to many brain regions (e.g. hippocampus, nucleus accumbens, thalamus, ventral tegmental area, substantia nigra)^[@R35]-[@R39]^, where EtOH only affects GABA~A~R transmission at concentrations far above those typically achieved during voluntary consumption by rodents or humans (≥ 50mM), both suppression and enhancement of GC GABA~A~R transmission occur at low, readily achieved concentrations of alcohol (9-31mM; [Fig. 2j,k](#F2){ref-type="fig"}). Thus, to the extent that EtOH actions at GABA~A~Rs influence acute EtOH sensitivity or voluntary consumption levels^[@R40],[@R41]^, the distinctively high sensitivity GC GABA~A~R transmission and clear variation in response magnitude and polarity across rodent genotypes ([Fig. 2i](#F2){ref-type="fig"}) highlights such actions as a potential cellular substrate for genotypic differences in EtOH phenotypes. Future studies should test whether experimental manipulations of GC GABA~A~R responses to EtOH influences EtOH sensitivity or consumption phenotype, and our identification of the molecular mediators of GABA~A~R responses (discussed below) should provide necessary targets for such endeavors.

Our findings also have important implications for interpreting behavioral data from knockout and transgenic mice, which are often created on a B6 background. In particular, genetic deletion of the α6 or δ subunit in B6 mice, which eliminates GC tonic GABA~A~R currents^[@R15],[@R18]^, does not affect EtOH-induced disruption of rotarod performance^[@R42],[@R43]^. However, studies in low EtOH consuming CD-1 mice clearly indicate that the cerebellum is the primary site of action for EtOH-induced disruption of performance on the rotarod^[@R12]^, and, although controversial^[@R21]^, studies in low drinking SDRs suggest that EtOH enhancement of tonic GABA~A~R inhibition in GCs is a primary mechanism of such disruption^[@R20]^. Our determination that EtOH has opposite actions on GC tonic GABA~A~R currents in B6 mice and SDRs may explain this apparent discrepancy. If the EtOH-induced suppression of tonic GABA~A~R currents observed in B6 mouse GCs is less disruptive of rotarod performance than the enhancement of tonic GABA~A~R currents observed in SDR GCs, then genetic deletions that eliminate tonic GABA~A~R currents in B6 mice would have less impact on EtOH disruption of rotarod performance than will manipulations of tonic GABA~A~R currents in SDR GCs. Importantly, B6 mice are less sensitive than D2 mice to EtOH disruption of rotarod performance^[@R8]^, suggesting that indeed EtOH-induced suppression of GABA~A~R tonic currents in B6 mice is less disruptive of rotarod performance than potentiation of GABA~A~R tonic currents in D2 mice. Thus, accurate interpretations of past and future behavioral studies of EtOH in rodents with genetic or pharmacological alteration of α6 or δ subunits will require electrophysiological assessment of the actions of EtOH on GC tonic GABA~A~R currents specifically in the line or strain of rodent being tested. Here we provide this information for five frequently studied genotypes: B6 mice, D2 mice, WSR mice, WSP mice, and SDRs.

EtOH-induced enhancement of GABA~A~R transmission {#S10}
-------------------------------------------------

In SDRs, EtOH-induced potentiation of GC GABA~A~R inhibition is mediated by an increase in action-potential dependent, vesicular GABA release from Golgi cells ([Fig. 3a,b](#F3){ref-type="fig"})^[@R19]-[@R21]^. The increase in vesicular GABA release causes an increase in the frequency of GC sIPSCs and the magnitude of the tonic GABA~A~R current, due to accumulation of GABA in the extrasynaptic space. It has been suggested that EtOH also binds directly to GC extrasynaptic GABA~A~Rs and increases their affinity for GABA, the degree of which is influenced by a nucleotide polymorphism in the GABA~A~R α6 subunit^[@R20]^. Such a polymorphism could represent a mechanism for genetic control of GC GABA~A~R sensitivity to EtOH. However, in agreement with several other studies^[@R19],[@R21]^, in our hands, even at 79mM, EtOH did not cause detectable potentiation of GC tonic GABA~A~R currents in the presence of TTX ([Fig. 3a,b](#F3){ref-type="fig"}), arguing against direct potentiation of extrasynaptic GABA~A~Rs by EtOH. Furthermore, since under physiological conditions (no TTX), EtOH-induced increased vesicular GABA release is the predominant cause of EtOH-enhanced GC tonic GABA~A~R currents^[@R19],[@R21]^, genetic control over that process is likely to be a more powerful control point. Indeed, here we demonstrate that the EtOH-induced increase in vesicular GABA release is mediated by suppression of NOS, and that genetic variation in nNOS expression across rodent genotypes powerfully controls the degree to which EtOH potentiates GC GABA~A~R transmission. Strikingly, based on our analysis of immunocytochemistry and bioassay, we estimate that the expression level of nNOS in the granule cell layer of B6 mice is about 25% of the levels expressed in SDRs and D2 mice ([Fig. 6](#F6){ref-type="fig"}). Correspondingly, less than 20% of B6 GCs exhibited EtOH potentiation of GC GABA~A~R tonic currents, compared to \>90% of SDR GCs and ∼50% of D2 GCs ([Fig. 2e](#F2){ref-type="fig"}). Our data do not address how blockade of nNOS leads to increased Golgi cell excitability, but recent studies suggest that suppression of the Na^+^/K^+^-ATPase and a K^+^ conductance contribute to the EtOH--induced increase in Golgi cell firing^[@R28]^, and both could be down-stream targets of NO. In particular, NO is known to increase Na^+^/K^+^-ATPase activity^[@R44]^, so EtOH induced suppression of nNOS could reduce Na^+^/K^+^-ATPase activity, with resultant depolarization of Golgi cells. Similarly, while the molecular identity of the K^+^ conductance that contributes to increased Golgi cell excitability is unclear^[@R28]^, many K^+^ conductances are positively modulated by NO, either directly or indirectly via NO-induced cGMP production^[@R45],[@R46]^. Thus, EtOH suppression of NOS could also contribute to the suppression of K^+^ channels that increases Golgi cell firing.

EtOH-induced suppression of GABA~A~R transmission {#S11}
-------------------------------------------------

It is widely accepted that enhancement of GABA~A~R transmission is a primary mechanism underlying the behavioral effects of EtOH^[@R40],[@R41]^. Contrary to this prevailing thinking, here we report that EtOH suppresses tonic GABA~A~R currents in several rodent genotypes ([Fig. 2](#F2){ref-type="fig"}). The suppression of tonic GABA~A~R is not accompanied by a decrease in the frequency of sIPSCs, and is not blocked by TTX, and is observed in physically isolated B6 GC responses to exogenous GABA, suggesting a direct action on the extrasynaptic GABA~A~Rs that mediate tonic inhibition ([Fig. 7](#F7){ref-type="fig"}). Recent studies of recombinantly expressed GABA~A~Rs with various point mutations indicate that GABA~A~R subunits may have multiple counteracting sites of action for EtOH, with the net effect of EtOH being determined by the balance of inhibitory and enhancement sites^[@R47]-[@R49]^. However, to our knowledge, this is the first report of EtOH suppressing native GABA~A~Rs *in situ*. Studies of cultured rat GCs indicated that EtOH suppressed GABA~A~R currents in some GCs but enhanced it in others, and the proportion of cells showing suppression was increased in cells that were recorded with the perforated-patch technique^[@R50]^, suggesting that endogenous kinases or other endogenous GABA~A~R modulators determines the polarity of action of EtOH. Indeed, we determined that elevated postsynaptic PKC activity occludes EtOH suppression of tonic GABA~A~R currents, and that genetic differences in PKC activity determine whether EtOH suppression of GC tonic GABA~A~R currents occurs in a given rodent genotype ([Fig. 8](#F8){ref-type="fig"}).

Interactions among EtOH targets determines net response {#S12}
-------------------------------------------------------

Taken together, our data demonstrate that there are two main mechanisms by which EtOH acts on GC GABA~A~R transmission: 1.) inhibition of nNOS which results in increased action-potential dependent vesicular release of GABA with a resultant increase in sIPSC frequency and tonic GABA~A~R current magnitude, and 2.) a direct inhibition of α~6~δ-containing GABA~A~Rs and the tonic GABA~A~R current they generate in cells with low PKC activity. Thus, genetic or pharmacological control over two distinct and opposing molecular actions of EtOH enables a fine tuning of GC tonic GABA~A~R responses along a spectrum from powerful enhancement to powerful suppression.

Methods {#S13}
=======

Preparation of brain slices {#S14}
---------------------------

All procedures conform to the regulations detailed in the National Institutes of Health *Guide for the Care and Use of Laboratory Animals* and were approved by the Animal Care and Use Committee of the Oregon Health and Science University. Cerebellar slices were prepared acutely on each day of experimentation^[@R14],[@R17]^. Male and female rodents (18-28 days old), randomized for each experiment, were housed between 2-6 animals/cage and maintained on a standard light/dark cycle. Animals were anaesthetized with Isoflurane and killed by decapitation. The whole brain was rapidly isolated and immersed in ice cold (0-2°C) artificial cerebrospinal fluid (ACSF) containing (in mM): 124 NaCl, 26 NaHCO~3~, 1 NaH~2~PO~4~, 2.5 KCl, 2.5 CaCl~2~, 2 MgCl~2~, 10 D-glucose, and bubbled with 95%O~2~/5% CO~2~ (pH 7.4). The cerebellum was dissected out of the brain and mounted, parallel to the sagittal plane, in a slicing chamber filled with ice cold (0-2°C) ACSF. Parasagittal slices (225μm) were made with a vibrating tissue slicer (Vibratome). Slices were incubated in warmed ACSF (33±1°C) for one hour after dissection and then held at 22-23°C until used. Kynurenic acid (1 mM) was included in the dissection, incubation and holding solution (to block glutamate receptors to reduce potential excitotoxic damage) but was omitted from the experimental solutions.

Electrophysiology {#S15}
-----------------

Slices were placed in a submersion chamber on an upright microscope, and viewed with an Olympus 60X (0.9 numerical aperture) water immersion objective with differential interference contrast and infrared optics. Slices were perfused with ACSF at a rate of ∼7ml/min at room temperature (22-24° C). Drugs were dissolved in ACSF and applied by bath perfusion. Visually identified granule cells were voltage-clamped (Vh = -60mV) with patch pipettes, constructed from thick-walled borosilicate glass capillaries and filled with an internal solution containing (in mM): CsCl 130, NaCl 4, CaCl~2~ 0.5, HEPES 10, EGTA 5, MgATP 4, Na~2~GTP 0.5, QX-314 5. Solutions were pH adjusted to 7.2-7.3 with CsOH. Electrode resistance was 4 to 10 MΩ. Cells were rejected if access resistance was greater than 15 MΩ, or if access resistance changed by \> 15%, or if there were condition-independent changes in holding current. Note, the intracellular \[Cl^-^\] sets E~Cl~- to ∼0mV, which for the holding potentials used in all experiments (-60mV), results in GABA~A~R currents being inward (downward deflections in displays of the holding current). Accordingly enhancement and block/suppression of tonic GABA~A~R-mediated currents are inward and outward respectively. In all cases, only one cell was recorded from a given slice. In cases where the slice was exposed to more than one drug or different doses of the same drug, the order of drug application was randomized across slices. In all cases of multiple drug exposures to the same slice, a stable baseline was obtained following washout of drug for a minimum of 4 minutes. However, control experiments were never done on slices that had been exposed to TTX, GABAzine, or incubated in L-NA as the efficacy and time required to adequately wash such drugs is preclusive of additional unrelated experimentation.

Immunocytochemistry {#S16}
-------------------

Slices were fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) for 17 hours. Slices were then washed and incubated for 40 minutes in blocking solution (PBS, 0.5% Triton X-100, and bovine serum albumin \[0.5mg/ml\]). Next, they were incubated for 1-2 days with primary antibody in PBS and Triton. Slices were washed 3 times (10 minutes each) in PBS, then incubated for 45 minutes with an Alexa-conjugated secondary antibody. Slices were mounted in Citifluor and imaged with confocal microscopy. See reagents below for source and dilution of antibodies used.

DAF-FM detection of NO production {#S17}
---------------------------------

We used DAF-FM as a fluorescent biochemical assay of cellular NO production^[@R51]^. Slices were incubated in the relevant experimental condition (control, control + 52mM EtOH, or control + 300μM L-NA) for a 30 minute equilibration period, followed by addition of the DAF-FM (1μM) + the relevant experimental condition for 30 minutes, followed by washout of DAF-FM in the continued presence of the relevant experimental condition for 30 minutes. Following the exposure protocol, slices were fixed (as for immunocytochemistry, see above), and processed for confocal microscopy. Whole field emission analysis largely eliminates subjective bias, and so DAF-FM experiments were not performed blind to the conditions of the experiment.

Confocal microscopy {#S18}
-------------------

Images were acquired with a Zeiss confocal LSM780 laser scanning Microscope, using accompanying Zeiss software for acquisition, processing and subsequent analysis. A laser line falling within 20nm of the peak absorbance was used for each of the various fluorophores, with appropriate excitation, dichroic and emission filters. One of two objectives was used for all experiments: a 20×, 0.8 N.A. Plan Apochromat air objective ([Fig. 4](#F4){ref-type="fig"}), or a 40×, 1.4 N.A. PlanApo oil-immersion objective ([Figs. 1](#F1){ref-type="fig"}**&**[6](#F6){ref-type="fig"} and [supplementary Figs. 3&4](#SD1){ref-type="supplementary-material"}). Pinhole diameter and slice step thickness were optimized for the objective used. For GABA~A~R subunit distribution studies ([Fig. 1](#F1){ref-type="fig"}), quantification of nNOS and GAD 65/67 expression ([Fig. 6d&g](#F6){ref-type="fig"}), and quantification of NO sensitive fluorophore (DAF-AM) fluorescence emission ([Fig. 4](#F4){ref-type="fig"}) stacks of image planes were acquired, and then projected into a single stacked image (10 μm thick). For a given fluorophore, digital gain and offset settings were identical for all images across all species and conditions. For quantification of GC encirclement by nNOS ([Fig. 6a-d](#F6){ref-type="fig"} and [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}), a single image plane at 10μm from the surface of the slice was analyzed as follows. Individual GCs were identified by nuclear stain Hoechst 33342, and the nNOS signal was amplified until ∼5% of the pixels were saturated. Subsequently, an experimenter, blind to the experimental condition, analyzed individual GC nuclei for percent encirclement by detectable nNOS signal (as in [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Values were obtained from at least 3 animals of each species, at least 2 slices from each animal and at least 5 distinct regions of each slice.

Analysis of GABA~A~R currents {#S19}
-----------------------------

Membrane currents were acquired at 20 kHz, filtered at 10 kHz, and analyzed with pClamp (v.6.3) software (Axon Instruments, Foster City, CA). For analysis and display of sIPSCs, data were filtered at 2-5 kHz. The absolutely objective methodology used for analysis of GABA~A~R currents (automated measurement at fixed time points) obviated experimenter blinding, thus collection and analysis of all electrophysiological experiments were not performed blind to the experimental condition. When quantifying sIPSC occurrence, sIPSCs were defined as current deflections that have an amplitude (measured from the mean current) greater than the peak-to-peak amplitude of the current noise and with a decay time constant at least 3-fold slower than the rise time. The tonic current was assessed by fitting the Gaussian distribution of all data points not skewed by synaptic events from a point 3 pA to the left of the peak value to the rightmost (smallest) value of the histogram distribution (see [supplemental Fig. 1](#SD1){ref-type="supplementary-material"} for examples). Drug-induced changes in tonic GABA~A~R current magnitude and sIPSC frequency were calculated by comparing the amplitude/frequency in the drug versus the mean amplitude/frequency of the currents before and after drug application.

Statistics {#S20}
----------

All data are expressed as the mean ± the standard error of the mean. One-way ANOVA was used to detect significant main effects, and Student\'s t-tests were used for post hoc-analyses, while all other statistical comparisons were made with unpaired or one-sample t-tests. In all cases, statistical tests were two-tailed and we set the threshold for significance at *P* \< 0.05. In some cases, parametric statistical techniques could not be used due to variable or antipodal responses that violated assumption of normally distributed data as determined by significant Shapiro-Wilk statistic (*P* \< .05). In these cases (i.e. [Figs. 2h](#F2){ref-type="fig"}, [3f](#F3){ref-type="fig"}, [6d,k&l](#F6){ref-type="fig"}, **and** [8d](#F8){ref-type="fig"}), we used non-parametric Kruskal-Wallis one-way analysis of variance tests with Dunn\'s method for pair wise comparison, or Mann-Whitney U tests where appropriate. In the figures, gray arrows point to an extended time scale of recording from different time points of the main trace. \* signifies *P* \< 0.05, \*\* signifies *P* \< 0.01, and \*\*\* signifies *P* \< 0.001. No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in the field^[@R14],[@R17],[@R19],[@R20]^.

Reagents {#S21}
--------

All reagents were from Sigma Chemicals (St. Louis, MO) except AP5, bicuculline, gabazine, kynurenic acid, NBQX (all from Ascent scientific, UK), and iodoacetic acid (from Acros/Fisher). Primary antibodies were (host/supplier/dilution): nNOS (rabbit/Cayman chemicals 160870/1:200), GAD65 (mouse/Millipore MAB 351/1:200), GAD67 (mouse/Millipore MAP 5406/1:200), α6 subunit of GABA~A~R (rabbit/Millipore AB5610/1:200) δ subunit of GABA~A~R (rabbit/Millipore AB9752/1:200). Secondary antibodies were various excitation maxima Alexafluors (Invitrogen) from appropriate hosts diluted 1:500. For some antibodies (α6 and δ subunit of GABA~A~R), specificity has been confirmed by lack of labeling in relevant knockout mice, for others (GAD 65 and 67) specificity has been confirmed by their labeling of a single band on western blots (see manufacturer website for details, and links therein). For those antibodies where such confirmation of specificity was not already available (nNOS), we confirmed specificity ourselves, by examining slices from nNOS knockout mice (*Nos1^tm1Plh^* homozygotes, backcrossed to C57BL/6J mice for \>10 generations, from Jackson Laboratory), which did not display detectable nNOS staining ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). Furthermore, for all of the antibodies we used, the general qualitative expression pattern within the cerebellum is similar to what has been shown with other antibodies in other reports and to our own studies with alternative antibodies. Importantly, for all of the crucial immunohistochemical studies (GABA~A~R subunits and nNOS), we have conducted parallel electrophysiological studies of the relevant proteins\' activity which confirm our histochemical assessments (see electrophysiological experiments in [Figs. 1](#F1){ref-type="fig"}**&**[6](#F6){ref-type="fig"} for functional confirmation of GABA~A~R subunit and NOS expression levels, respectively).
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![B6 and D2 mouse GCs exhibit similar magnitude tonic currents mediated by α6 and δ subunit containing GABA~A~Rs. **a.** Example traces showing block of tonic current by GABA~A~R antagonist GABAzine (10μM) in GCs from B6 (**top**) and D2 (**bottom**) mice. Note, in this and all other figures, the gray arrows point to an expanded time scale of recording from different time points of the main traces (coming from the region of the main trace that the back of the arrow extrapolates to), showing sIPSCs and block by GABAzine. **b.** Confocally acquired fluorescence images of cerebellar slices from B6 (**top**) and D2 (**bottom**) mice (representative scans from *n =* 8 slices from 4 B6s and *n* = 7 slices from 4 D2s) showing α6 subunit of the GABA~A~R (red) expression exclusively in the granule cell layer (identified by high density of GC nuclei, labeled blue with nuclear stain Hoechst, beneath the Purkinje cell layer, labeled green with antibody to GAD, left panels). Right panels are blow ups of boxed region showing α6 staining is around GC somas (labeled blue with nuclear stain Hoechst), and in GC dendrites located in the glomerulus (indicated by lack of nuclear stain, and colocalization with staining for GAD (green) which labels Golgi cell axon terminals). Arrow points to a representative α6 labeled glomerulus. GCL=GC layer, PCL=Purkinje cell layer, ML=Molecular layer. **c.** Example traces showing block of tonic current by GABA~A~R antagonist furosemide (100μM, at which concentration it is specific for GABA~A~Rs containing the α6 subunit) in GCs from B6 (**top**) and D2 (**bottom**) mice. Gray arrows point to expanded time scale of recording from different time points of main traces, showing lack of effect of furosemide on sIPSCs. **d.** Same as C&D except red immunostain comes from antibody for the δ subunit of the GABA~A~R (representative scans from *n* = 5 slices from 4 B6s and *n* = 9 slices from 6 D2s). **e.** Example traces showing enhancement of tonic current by GABA~A~R agonist THIP (500nM, at which concentration it is specific for GABA~A~Rs containing the δ subunit) in GCs from B6 (**top**) and D2 (**bottom**) mice. **f.** Example traces showing lack of effect of diazepam (300nM) on tonic GABA~A~R current in GCs from B6 (top) and D2 (bottom) mice. **g.** Plot summarizing mean tonic current induced by THIP (B6, *n* = 18 cells; D2, *n* = 10), and blocked by furosemide (B6, *n* = 17 cells; D2*, n* = 17) and GABAzine (B6, *n* = 12 cells; D2, *n* = 12), and lack of effect of diazepam (B6, n = 7 cells; D2, n = 9) in B6 and D2 mouse GCs. Furosemide-, THIP- and GABAzine-, but not diazepam-induced currents (*n* = 16 cells, *P* = .49), are all significantly different from zero *P* \< 0.05 using one-sample *t*-tests, and none are significantly different between strains (furosemide: *P* = .25; THIP: *P* = .27; GABAzine: *P* = .45, unpaired *t*-tests).](nihms560005f1){#F1}

![The impact of EtOH on GC tonic GABA~A~R currents varies in polarity and magnitude across rodent genotypes with divergent EtOH consumption phenotypes. **a.** Representative data showing that EtOH increases sIPSC frequency (insets indicated by gray arrows) and potentiates the tonic GABA~A~R current magnitude (main trace) in SDR GCs. **b-d.** Representative data showing that EtOH can either potentiate (**b**), suppress (**d**) or have no impact (**c**) on tonic GABA~A~R currents in D2 and B6 GCs. **e.** Plot of proportion of GCs showing potentiation, suppression or no effect of EtOH on tonic GABA~A~R currents in SDR, B6 and D2 GCs. **f&g.** Representative traces showing that both outward (**f**) and inward (**g**) currents induced by EtOH are abolished by the GABA~A~R antagonist, GABAzine (10μM). For cells that had shown significant EtOH-induced inward and outward currents under control conditions, in the presence of GABAzine, the mean EtOH-induced current was -0.09 ± 0.16 pA and -0.13 ± 0.22 pA, i.e. not significantly different to baseline for both (Inward: *n* = 13 cells, *P* = .55; outward: *n* = 14, *P* = 0.53, one-sample *t*-tests). **h.** Plot of the mean magnitude and polarity of the GC GABA~A~ tonic current to EtOH for all cells tested from SDRs, B6s and D2s (\* indicates significantly different, *P* \< 0.05). **i.** Plot of the mean magnitude and polarity of the GC GABA~A~ tonic current to EtOH for all cells from each type of rodent: SDRs (*n* = 47 cells), D2 mice (*n* = 31), WSP mice (*n* = 9), WSR mice (*n* = 7), and B6 mice (*n* = 39). Numbers at bottom of chart show the typical amount of EtOH consumed (in g/kg/day) for each type of rodent in published free access two or three bottle choice studies (from^[@R7],[@R22],[@R26]^). **j.** Representative traces showing that concentrations of EtOH as low as 9mM suppress and enhance tonic GABA~A~R currents in B6 mouse and SD rat GCs respectively. **k.** Plot showing dose response relationship for EtOH-induced suppression and enhancement of tonic GABA~A~R current from baseline in B6 mouse (black) and SD rat (white) GCs respectively (SD rat: all \*\*\**P* \< .001; B6: \*\*\**P* \< .001 \[9mM\], \*\*\**P* \< .001 \[31mM\], \**P* = .028 \[52mM\]; *P* = .025 \[79mM\], one-sample *t*-tests). **l.** Plot of EtOH induced change in tonic GABA~A~R current magnitude versus EtOH-induced change in noise variance for each cell examined (all concentrations of EtOH tested 9-79 mM are included; SD rat: *n* = 16 cells; B6: *n* = 27; D2: *n* = 36).](nihms560005f2){#F2}

![EtOH-induced potentiation of GC tonic GABA~A~R current is mediated by suppression of NOS and consequent increase in action potential dependent vesicular release of GABA. **a.** Representative recording shows that blocking action potentials with TTX (500nM) abolishes the EtOH (52mM)-induced increase in sIPSCs and tonic GABA~A~R current magnitude. **b.** Chart depicts mean magnitude of EtOH-induced (52mM and 79mM) increase in tonic GABA~A~R current under control conditions (*n* = 47 cells for 52mM; *n* = 15 for 79mM) and in the presence of TTX (500nM; *n* = 11 cells from 3 animals for 52mM; *n* = 8 cells from 2 animals for 79mM). EtOH effects in TTX did not significantly differ from baseline, *P* = .54 for 52mM EtOH and *P* = .36 for 79mM EtOH; \*\*\* indicates significantly different from baseline *P* \< 0.001 by one-sample *t*-tests. **c.** Representative recording shows that the NOS substrate inhibitor, L-NMMA (100μM) increases the frequency of sIPSCs and the tonic GABA~A~R current in SDR GCs. L-NMMA had no effect on GC currents in the presence of the GABA~A~R antagonist, GABAzine (10μM, *n* = 4 cells from 2 animals, not shown). **d.** Plot of mean increase in sIPSC frequency (left; 100uM: *n* = 22 cells from 10 animals, 48.34 ± 23.97%, *P* = .057; 200uM: *n* = 16 cells from 5 animals, 120.37 ± 53.94%, \**P* = .044, by one-sample *t*-tests) and tonic GABA~A~R current magnitude (right; 100uM: *n* = 22 cells, 2.56 ± 0.56, \*\*\**P* \< .001; 200uM: *n* = 16, 6.20 ± 1.38, \*\*\**P* \< .001, by one-sample *t*-tests) induced by L-NMMA in SDR GCs. **e.** Representative recordings showing that pre-incubation of slices and maintained presence in the NOS substrate inhibitor, L-NA (300μM), suppresses the EtOH-induced increase in sIPSCs and tonic GABA~A~R current in SDR (**top**) and D2 (**bottom**) GCs. **f.** Plots of mean increase in sIPSC frequency (**top**) and tonic GABA~A~R current magnitude (**bottom**) induced by EtOH (52mM) in SDR (white; *n* = 10 cells from 3 animals for L-NA treated slices, sIPSCs: \**P* = .015; tonic GABA~A~R current: \**P* = .026) and D2 (gray; *n* = 8 cells from 2 animals for L-NA treated slices, sIPSCs: \**P* = .015; tonic GABA~A~R current: \**P* = .029, comparisons between groups by Mann-Whitney U tests) GCs under control conditions and in slices treated with L-NA (300μM). **g.** Representative traces showing that the NOS antagonist, L-NMMA (200μM) does not block nicotine (500nM)-induced increases in tonic GABA~A~R currents in SDR GCs. **M**ean increase in tonic GABA~A~R current magnitude induced by nicotine (500nM) in SDR GCs under control conditions = 17.56 ± 3.24 pA and in slices treated with L-NMMA (200μM) = 21.36 ± 5.61 pA (*n* = 5 cells from 2 animals, *P* = 0.46, paired *t*-test).](nihms560005f3){#F3}

![EtOH suppresses tonic production of NO in the granule cell layer. **a-c**. Confocally acquired images of fluorescence emission from SDR cerebellar slices that were pre-soaked in either the NO-sensitive fluorophore, DAF-FM alone (**a**), or combined with the NOS antagonist, L-NA (300μM; **b**) or EtOH (52mM; **c**). **d.** Plot of mean DAF fluorescence emission across the granule cell layer under control conditions (*n* = 20 slices from 2 animals)*,* or when treated with L-NA (300μM, *n* = 22 slices from 2 animals) or EtOH (52mM, *n* = 20 slices from 2 animals). \*\*\* indicates significantly different from control slices, *P* \< 0.001, unpaired *t*-tests.](nihms560005f4){#F4}

![EtOH inhibition of NOS increases Golgi cell firing. **a-c.** Representative traces show action potentials (APs) in current-clamped Golgi cells under various conditions: **a.** Control (**top**) versus the NOS antagonist, L-NMMA (200μM, **bottom**) in the same cell, **b.** control (**top**) versus EtOH (52mM, **bottom**) in the same cell, and **c.** in the presence of the NOS antagonist, L-NA (300μM, top) alone or with EtOH (52mM, bottom) in the same cell. **d.** Plot of mean increase in Golgi cell AP firing frequency in L-NMMA (200μM; *n* = 4 cells, \**P* = .022, one-sample *t*-test), EtOH (52μM; *n* = 9, \*\**P* = .007), or EtOH after incubation and in the presence of the NOS antagonist, L-NA (300μM, *n* = 9, *P* = .24, one-sample *t*-tests). Unpaired *t*-test comparing conditions, \*\**P* = .001.](nihms560005f5){#F5}

![Differential expression of nNOS underlies differences in EtOH-induced potentiation of GC GABA~A~R transmission. **a-c.** Confocally acquired images of immunocytochemistry for nNOS (red) and nuclear stain Hoechst (blue) in the granule cell layer of SDR (**a**), B6 (**b**), and D2 (**c**) cerebellum. **d.** Plot of mean percent encirclement of GC soma/nuclei (as determined in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}) for SDR (white; *n =* 2694 cells from 2 slices from 2 animals), B6 (black; *n* = 2316 cells from 6 slices from 2 animals) and D2 (gray; *n* = 3398 cells from 5 slices from 2 animals) cerebellum. \*\*\* indicates significantly different, *P* \< 0.001. **e-f.** Confocally acquired images of immunocytochemistry for nNOS (red), GAD 65/67 (green) and nuclear stain Hoechst (blue) in the granule cell layer of SDR (**e**) and B6 (**f**) cerebellum. White arrows point to the cell body of a Golgi cell in each figure. **g.** Plot of mean ratio of fluorescence emission intensity for nNOS staining versus GAD 65/67 staining in individual Golgi cells in SDR (white, *n* = 6 slices), B6 (black, *n* = 6), and D2 (gray, *n* = 7, each from 2 animals) cerebellum (ratio in B6 = 0.82 ± 0.04, *n* = 6 SDR = 2.05 ± 0.10, D2 = 1.65 ± 0.14) \*\*\* *P* \< 0.001 by unpaired *t*-tests. **h-j.** Representative recordings showing increase in tonic GABA~A~R current and sIPSC frequency induced by NOS substrate inhibitor, L-NMMA (200μM), in SDR (**h**), B6 (**i**) and D2 (**j**) GCs. **k,l.** Plots of mean increase in sIPSC frequency (**k**) and tonic GABA~A~R current magnitude (**l**) induced by L-NMMA (200μM) in SDR (white; *n* = 16 cells), B6 (black; *n* = 11), and D2 (gray; *n* = 17) GCs. \* *P* \< 0.05 by Mann-Whitney U tests.](nihms560005f6){#F6}

![EtOH-induced suppression of tonic GABA~A~R current in B6 and D2 GCs is due to direct action on GABA~A~Rs. **a.** Plot of mean EtOH-induced change in sIPSC frequency in B6 GCs that exhibited EtOH-induced potentiation, suppression or no change of tonic GABA~A~R current. \*\**P* \< .01 by one-sample *t*-tests. **b.** Representative recordings showing that EtOH-induced suppression of tonic GABA~A~R current in B6 (**top**) or D2 (**bottom**) GCs is not prevented by blocking action potential dependent release of GABA with TTX (500nM). **c.** Plot of mean EtOH-induced change in tonic GABA~A~R current under control conditions or in TTX (500nM) shows that TTX abolishes responses to EtOH in SDR GCs (white; *n* = 47 cells for control, *n* = 11 for TTX, \*\*\**P* \< .001), has no effect on responses to EtOH in B6 GCs (black; *n* = 39 for control, *n* = 10 for TTX, *P* = .76) and converts mean response to EtOH from potentiation to suppression in D2 GCs (gray; *n* = 31 for control, *n* = 9 for TTX, \*\**P* = .003, by unpaired *t*-tests). **d.** Representative trace showing GC holding current during whole-cell recording configuration and upon transition to nucleated-patch recording configuration. Note loss of tonic GABA~A~R current and sIPSCs (insets) upon excision of the nucleated patch from the slice. **e.** Representative trace showing a nucleated patch recording from a B6 GC in the presence of TTX, during application of exogenous GABA (100nM) and subsequently EtOH (52mM), which suppresses the exogenous GABA evoked current. Note, after wash of exogenous GABA, subsequent application of the GABA~A~R antagonist, GABAzine (10μM) does not generate any current, confirming that the nucleated patch is isolated from endogenous sources of GABA from the slice. **f.** Plot of mean percent block by EtOH of tonic GABA~A~R currents in whole cell recordings (black, *n* = 20 cells, \*\*\**P* \< .001) and of currents evoked by exogenous GABA applied to nucleated patches (white, *n* = 6, \**P* = .047. All data from B6 GCs.](nihms560005f7){#F7}

![Direct suppression of tonic GABA~A~R current by EtOH is prevented by postsynaptic PKC activity. **a**. Representative recording from an SDR GC showing that in the presence of TTX (500nM) in the bath, and PKC inhibitor, Calphostin C (100 nM), in the recording electrode, EtOH suppresses the tonic GABA~A~R current. **b.** Representative recording from a B6 GC showing that in the presence of TTX (500nM) in the bath, and PKC activator, PMA (100 nM), in the recording electrode, EtOH does not suppress the tonic GAB~A~R current. **c.** Plot of mean EtOH-induced change in tonic GABA~A~R current in the presence of TTX (500nM), in B6 GCs (black) with (*n* = 13 cells) or without (*n* = 8) PMA in the recording electrode, and in SDR GCs (white) with (*n* = 20) or without (*n* = 11) Calphostin C in the recording electrode. \* indicates significantly different from baseline, \**P* \< 0.05 by one-sample *t*-tests. **d.** Plot of mean EtOH-induced change in tonic GABA~A~R current in normal ACSF (no TTX added), in B6 GCs (black) with (*n* = 6 cells) or without (*n* = 39) PMA in the recording electrode, in SDR GCs (white) with (*n* = 16) or without (*n* = 47) Calphostin C in the recording electrode. \*\**P* = .003, † = .089, by Mann-Whitney U tests.](nihms560005f8){#F8}
